{"id":"W3087179831","doi":"10.1182/blood.2020006578","title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"Cilag; Janssen Pharmaceuticals; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Servier; Juno Therapeutics; Eisai; TG Therapeutics; H. Lundbeck A/S; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Kite Pharma; Unum Therapeutics; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen","keywords":"Venetoclax; International Prognostic Index; Medicine; Internal medicine; Diffuse large B-cell lymphoma; Rituximab; Vincristine; CHOP; Prednisone; Hazard ratio; Population; Tolerability; Oncology; Cyclophosphamide; Lymphoma; Gastroenterology; Adverse effect; Confidence interval; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002336774,0.0002522485,0.0005163269,0.00004344677,0.00007632143,0.00001110648,0.00006578492,0.00004993311,0.00002722757],"category_scores_gemma":[0.00003007196,0.0001655812,0.0001228003,0.0001356056,0.00001652301,0.00003439668,0.00003078854,0.00001886107,0.00002025705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000281211,"about_ca_system_score_gemma":0.0002474185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000189379,"about_ca_topic_score_gemma":0.00005477077,"domain_scores_codex":[0.9987935,0.0000181702,0.0002856968,0.0003704567,0.0002709108,0.0002612859],"domain_scores_gemma":[0.9991134,0.0000802173,0.0001359074,0.0003151365,0.0001039782,0.0002513235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.008195657,0.7271551,0.2496959,0.0002450531,0.001940648,0.000411285,0.006494706,0.00001390926,0.00006694672,0.00002140652,0.0002543429,0.005505056],"study_design_scores_gemma":[0.824667,0.135794,0.02357814,0.0000741495,0.003030805,0.000006487524,0.0004493232,0.0002285515,0.008022279,0.000003523685,0.003939407,0.0002062819],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959393,0.0002444602,0.000008745074,0.0001486881,0.00003037641,0.00317944,0.0002215096,0.00004526921,0.0001822822],"genre_scores_gemma":[0.9984937,0.00004866882,0.0001678618,0.0002217861,0.00008912601,0.0006599289,0.0001724,0.0000397706,0.0001067084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8164714,"threshold_uncertainty_score":0.6752205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01977755846897808,"score_gpt":0.2736588602511703,"score_spread":0.2538813017821921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}